RE: FDA US Home Trial - what programme would that be?26 Nov 2020 10:45
Guys...why do you think the Akron news was buried in the Placing RNS...
The US has been played down.
Interferon supplier is in the US.
Akron our manufacturer is in the US.
Numis Securities have two offices - London and New York
Clinigen brought on way ahead of time.
Phase 3 to be 20 UK hospitals plus 20 countries (US being one of them)
and we get a mention in this Home Land Security testimony:
You might find this interesting from USA too:
'New antivirals are also being developed for mild outpatient cases, including MK-4482 from Merck and Synairgen’s SNG001. These have been facilitated by Operation Warp Speed and the NIH’s ACTIV-2 (Adaptive Platforms Treatment Trial for Outpatients with COVID-19) trials.7 Although we are in the first stages of these clinical trials, the preliminary data seems promising.'
https://www.hsgac.senate.gov/imo/media/doc/Testimony-Jha-2020-11-19.pdf
SNG have mentioned working closely with Govt regulators.
and in the investors webinar last week said if the results were good they expect to sell 100,000 14 x 1/day units per month of SNG001 @ around 3000 dollars per unit for Government stock piles. (correct me if I'm wrong but didn't he say dollars and I'd say Govt is plural in this case.
I have felt for a time there is more to all this and the trading patterns - large trades after hours is not just shorters...I suspect it's more about sales to US investors and I don't think they have to declare same thresholds as in the UK.